Revenue GrowthConsistent double‑digit revenue growth (~36% in 2025) demonstrates improving commercial traction and product adoption across channels. Sustained top‑line expansion supports scale, investment in distribution, and the potential to absorb fixed costs, aiding durable profitability recovery.
Conservative Balance SheetVery low leverage (debt/equity ~0.02) and a meaningful equity increase (~41.1M) provide financial flexibility while the company works toward profitability. This conservative capital structure reduces short‑term refinancing pressure and supports strategic investment or funding rounds if needed.
Consumable Product ModelRevenue derives from consumable nasal products sold via multiple channels (direct, resellers, pharmacies), creating recurring unit demand and predictable replenishment cycles. That consumable-driven model supports steady revenue cadence and customer retention over time.